Edward Thomas Ryan, D.T.M.&H., M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cholera | 113 | 2022 | 759 | 16.690 |
Why?
|
| Vibrio cholerae O1 | 48 | 2022 | 227 | 9.270 |
Why?
|
| Antibodies, Bacterial | 78 | 2022 | 1457 | 9.160 |
Why?
|
| Cholera Vaccines | 46 | 2022 | 250 | 9.070 |
Why?
|
| O Antigens | 21 | 2022 | 172 | 7.190 |
Why?
|
| Typhoid Fever | 30 | 2023 | 165 | 7.140 |
Why?
|
| Salmonella typhi | 25 | 2023 | 177 | 5.980 |
Why?
|
| Vibrio cholerae | 55 | 2022 | 813 | 5.850 |
Why?
|
| Travel | 38 | 2023 | 741 | 4.490 |
Why?
|
| Bangladesh | 77 | 2022 | 794 | 3.630 |
Why?
|
| Immunoglobulin A | 49 | 2022 | 962 | 3.600 |
Why?
|
| Diarrhea | 29 | 2021 | 1370 | 2.970 |
Why?
|
| Immunologic Memory | 27 | 2022 | 1385 | 2.840 |
Why?
|
| Antigens, Bacterial | 24 | 2022 | 1202 | 2.760 |
Why?
|
| Vaccines, Conjugate | 11 | 2021 | 329 | 2.580 |
Why?
|
| Vibrio cholerae O139 | 13 | 2021 | 50 | 2.390 |
Why?
|
| Vaccination | 33 | 2022 | 2963 | 2.280 |
Why?
|
| Immunoglobulin M | 23 | 2022 | 1532 | 2.100 |
Why?
|
| Immunity, Mucosal | 11 | 2020 | 486 | 2.040 |
Why?
|
| Immunoglobulin G | 58 | 2022 | 4486 | 1.950 |
Why?
|
| Salmonella paratyphi A | 8 | 2017 | 39 | 1.920 |
Why?
|
| Paratyphoid Fever | 6 | 2016 | 32 | 1.740 |
Why?
|
| Cholera Toxin | 31 | 2022 | 552 | 1.720 |
Why?
|
| Typhoid-Paratyphoid Vaccines | 3 | 2020 | 36 | 1.690 |
Why?
|
| Bacteremia | 12 | 2015 | 973 | 1.620 |
Why?
|
| Travel Medicine | 8 | 2019 | 81 | 1.610 |
Why?
|
| B-Lymphocytes | 26 | 2022 | 4928 | 1.500 |
Why?
|
| Immunity, Humoral | 5 | 2020 | 584 | 1.460 |
Why?
|
| Communicable Disease Control | 9 | 2018 | 812 | 1.240 |
Why?
|
| Antibody-Producing Cells | 10 | 2021 | 151 | 1.200 |
Why?
|
| Parasitic Diseases | 4 | 2021 | 77 | 1.090 |
Why?
|
| Disease Outbreaks | 15 | 2020 | 1728 | 1.060 |
Why?
|
| Salmonella Infections | 3 | 2015 | 182 | 1.040 |
Why?
|
| Communicable Diseases | 10 | 2018 | 800 | 1.040 |
Why?
|
| Vaccines, Combined | 2 | 2021 | 65 | 1.040 |
Why?
|
| Diarrhea, Infantile | 2 | 2015 | 127 | 1.010 |
Why?
|
| Escherichia coli Infections | 7 | 2018 | 552 | 1.000 |
Why?
|
| Serologic Tests | 5 | 2020 | 383 | 0.970 |
Why?
|
| Lipopolysaccharides | 19 | 2022 | 2267 | 0.970 |
Why?
|
| Feces | 19 | 2022 | 1382 | 0.960 |
Why?
|
| Carrier State | 4 | 2021 | 540 | 0.940 |
Why?
|
| Antibodies, Viral | 15 | 2022 | 3010 | 0.910 |
Why?
|
| Child, Preschool | 71 | 2022 | 41221 | 0.880 |
Why?
|
| Antibody Formation | 10 | 2022 | 1423 | 0.860 |
Why?
|
| Virus Diseases | 4 | 2021 | 691 | 0.820 |
Why?
|
| Mucous Membrane | 5 | 2019 | 670 | 0.810 |
Why?
|
| Bacterial Proteins | 13 | 2022 | 4016 | 0.810 |
Why?
|
| Administration, Oral | 22 | 2021 | 3963 | 0.800 |
Why?
|
| Salmonella | 4 | 2022 | 129 | 0.780 |
Why?
|
| Dysentery, Bacillary | 4 | 2022 | 84 | 0.750 |
Why?
|
| Enterotoxigenic Escherichia coli | 6 | 2018 | 32 | 0.750 |
Why?
|
| Bacterial Vaccines | 6 | 2009 | 420 | 0.740 |
Why?
|
| Host-Pathogen Interactions | 6 | 2021 | 1490 | 0.740 |
Why?
|
| Child | 81 | 2022 | 74388 | 0.710 |
Why?
|
| Vitreous Body | 3 | 2010 | 403 | 0.700 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 3 | 2019 | 599 | 0.700 |
Why?
|
| Humans | 249 | 2023 | 717280 | 0.680 |
Why?
|
| Adolescent | 87 | 2022 | 85143 | 0.650 |
Why?
|
| Measles | 4 | 2022 | 171 | 0.650 |
Why?
|
| Enterotoxins | 5 | 2016 | 380 | 0.640 |
Why?
|
| Antifungal Agents | 1 | 2022 | 708 | 0.630 |
Why?
|
| Endophthalmitis | 3 | 2010 | 261 | 0.630 |
Why?
|
| Young Adult | 72 | 2022 | 56249 | 0.610 |
Why?
|
| Tetanus Toxin | 2 | 2017 | 49 | 0.610 |
Why?
|
| Dehydration | 4 | 2022 | 239 | 0.600 |
Why?
|
| Disease Transmission, Infectious | 3 | 2018 | 544 | 0.590 |
Why?
|
| Disasters | 3 | 2006 | 484 | 0.590 |
Why?
|
| Rubella | 3 | 2022 | 45 | 0.580 |
Why?
|
| Measles-Mumps-Rubella Vaccine | 4 | 2022 | 66 | 0.580 |
Why?
|
| Vaccines, Inactivated | 12 | 2019 | 182 | 0.570 |
Why?
|
| Adult | 119 | 2022 | 212470 | 0.570 |
Why?
|
| Mumps | 3 | 2022 | 66 | 0.560 |
Why?
|
| Immunization | 9 | 2020 | 1278 | 0.550 |
Why?
|
| Shigella | 4 | 2022 | 80 | 0.540 |
Why?
|
| Vaccines, Attenuated | 7 | 2022 | 329 | 0.530 |
Why?
|
| Plasma | 1 | 2018 | 573 | 0.530 |
Why?
|
| Female | 137 | 2022 | 377934 | 0.510 |
Why?
|
| Entamoebiasis | 1 | 2013 | 14 | 0.510 |
Why?
|
| Campylobacter Infections | 1 | 2013 | 34 | 0.500 |
Why?
|
| Bacterial Toxins | 6 | 2016 | 960 | 0.500 |
Why?
|
| Pandemics | 12 | 2021 | 7292 | 0.500 |
Why?
|
| Fimbriae Proteins | 8 | 2015 | 137 | 0.500 |
Why?
|
| Vaccines, Synthetic | 7 | 2022 | 633 | 0.490 |
Why?
|
| Infant | 41 | 2022 | 34574 | 0.490 | |